A carregar...
Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage
BACKGROUND: To hasten cancer drug development, new paradigms are needed to assess therapeutic efficacy. In a randomized phase II study in patients with renal cell carcinoma, 10 μg/kg bevacizumab (Avastin(®); Genentech, Inc., South San Francisco, CA) administered every 2 weeks resulted in a longer ti...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3306833/ https://ncbi.nlm.nih.gov/pubmed/18827177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2008-0016 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|